Friday, June 8, 2012


The Federal Reserve and Alan Greenspan engineered the greatest financial catastrophe in history of the planet. The Federal Reserve must be audited and abolished! Audit the US gold in Fort Knox. Prosecute the Wall Street criminals. Reinstate Glass-Steagall. Enforcement of regulations is key. Watch Greece and Europe's economic troubles foretell our own future in America. As Europe falls, we fall because our Global economy is dependent on borrowed money and we have reached a point where we can no longer support the debt we have.I believe something much bigger and more earth shaking is headed our way in 2012-13 and will make an economic collapse pale in comparison. Its called the breakdown of society coupled with massive wars caused by the global financial crash. all of life revolves around the dollar bill. ALL OF IT. money caused the apocalypse. but what if that whole plate displacement theory thing comes to pass? global earthquakes, tsunamis, volcanoes...very real, very scary stuff. if some huge act of nature starts in 2012...humanity has little chance of making it past. were so un-advanced as a species its funny. but then its not. total panic is only Months away from now, people in America still think it cant fail and refuse to believe it will happen to America simply because its "America" It not only going to fail but its going to be an Arena of Death, from sick, suicides, murders, death from being killed by the Military, people vs the Military People will go house to house invading homes, killing occupants trying to survive, people are going to be huddled in camps protected by the Military

Yamada – Gold & Silver at Crucial Points in This Cycle

from King World News

With gold trading near the $1,620 level and silver approaching $30, today King World News is pleased to share with readers a piece of legendary technical analyst Louise Yamada’s “Technical Perspectives” report. This information is not available to the public and we are grateful to Louise for sharing her incredible work with KWN readers globally.

Continue Reading at…

Have Gold, Silver, & Mining Stocks Bottomed?

On Friday, the price action in gold caught the attention of most market participants as gold put in a monster move to the upside in light of risk assets such as the S&P 500 selling off sharply. In fact, gold futures rallied nearly $58 per troy ounce on Friday (+3.71%) while the S&P 500 Index sold off over 32 handles (-2.46%).

Monday saw some profit taking in gold and silver futures as Friday’s monster gains had to be digested. Short term traders were locking in profits, but overall the price action remains quite bullish at the moment. The gold miners remained extremely strong into the bell on Monday as buyers bid up prices in the afternoon to push them nearly 1.65% higher for the trading session.

Long time readers understand that I am a gold bull in the longer-term and have been for quite some time. Unlike some gold bugs, I will discuss the downside in precious metals from time to time even though it generally fills up my email inbox with some rather rude and hate-filled emails.

My view of gold and silver is that they are senior currencies. With that being said, I monitor the value of gold in U.S. Dollars and recognize that a stronger U.S. Dollar in the longer-term is not necessarily bullish for gold. Yes both gold and the Dollar can rally together, but mutualistic price action generally does not last for long periods of time. (more)

The Bond Rally is OVER: These Stocks Are a Much Better Investment

The grand sum of $1.4 trillion is a remarkably large number, no matter how you slice it. It's so large that it can single-handedly impact the direction of the stock market [1]. And thanks to recent events, it is a number you should be thinking about.

That huge sum of the money is the amount that has been shifted from stock funds to bond [2] funds during the past five years. It's a fairly historic shift, but may likely have run its course. History tells us so.

Over the past century, investors have poured into bonds [2] during periods of severe economic crises that were often associated with higher inflation [3] and higher interest rates. The most recent bond rally, back in the 1970s, was a perfect example. A lengthy period of stagflation pushed rates toward (and eventually past) the double-digit mark on the heels of anemic economic growth and rising inflation. Many investors came to the same conclusion: who would want to own stocks when a risk-free bond can deliver 7%, 8% or even 10% annualized gains? (more)


Over the past week, we've seen gold shares gain sponsorship without the physical gold metal rising. Perhaps this was the "canary in the coal mine" as they say, but gold prices roared ahead yesterday from a low of $1545 to a high of $1632 before closing at $1627. This put in place a rather bullish key reversal higher from major support between $1500-to-$1550. We find this rather positive for further gains, which many would equate to some level of European/US/Chinese liquidity measures.

But what we find more interesting is the fact that the Gold Share/Gold Futures Ratio (GDX/$GOLD) nearly reached the lows it formed in October-2008 at roughly .25. Thereafter, a rather spirited rally began to the benefit of GDX; and we look for the same type of run to develop at this point. Clearly the 30-week stochastics of the ratio is at oversold levels; and also confirming this is the longer-dated 21-week RSI that hit oversold. The last time the 21-week hit oversold, then the aforementioned spirited rally began.

Gdx-gold 6-2-12

Hence, we believe we are in the nascent stages of a bullish run in gold and gold shares, with gold shares taking the lead. We are buyers of gold shares on weakness; and look to be involved in the trade for many months. Stop losses can put placed at the recent lows or a bit higher.

Crocs, Inc. (NasdaqGS: CROX)

Crocs, Inc is a designer, manufacturer and distributor of footwear and accessories for men, women and children. At year-end 2011, Crocs sold its products in more than 90 countries through domestic and international retailers and distributors and directly to end-user consumers through its company-operated retail stores, outlets, kiosks and Webstores. It also offers accessories and apparel, which generated approximately 3.7% of its total revenues during the year 2011. Its footwear products are divided into four product offerings: Core-Comfort, Active, Casual and Style. The Core product offering primarily includes molded products that are derivatives of the original Crocs Classic designs. The Active product offering includes sport inspired products and footwear suited for activities, such as boating, walking, hiking and even recovery after workouts. The Casual product offering includes sporty and relaxed styles. The Style product offering includes stylish products.

Please take a look at the 1-year chart of CROX (Crocs, Inc.) below with my added notations:

There are (2) main price levels to watch on CROX. First, the $18 level (navy) was not only resistance back in November and May, but it was also a key level of support from January thru March. Next, $16 (red) has also been both a level of resistance from November into January and a support in October, November and currently.

The Tale of the Tape: The main levels to watch on CROX are $16 and $18. You could buy CROX if it comes down to $16, or short the stock if it breaks below the $16. If the stock rallies back up to $18 you could enter a short position, or you could buy the stock if it breaks back above $18.

Chart of the Day - Pharmacyclics (PCYC)

The "Chart of the Day" is Pharmacyclics (PCYC), which showed up on Tuesday's Barchart "All-Time High" list. Pharmacyclics on Tuesday rallied to a new all-time high of 34.17 and closed up 5.28%. TrendSpotter has been long since May 16 at $29.31. In recent news on the stock, Roth Capital on June 5 reiterated its Buy rating on the stock and its $42 target and said that Pharmacyclics' Phase II data for its ibrutinib cancer treatment is "dazzling." Pharmacyclics, with a market cap of $2.1 billion, is a pharmaceutical company developing products to improve upon therapeutic approaches to cancer, atherosclerosis and retinal disease.